Magnesium and Cognition After Stroke

Condition(s) studied

Investigational drug(s) / intervention(s)

Kölner Neuropsychologische Screening für Schlaganfall-Patienten: The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.

Study summary

Cognitive impairments such as memory impairments, word-finding difficulties, compromised orientation and perception are often observed in stroke patients.

Low serum-mg-concentrations are associated with cognitive impairments in ischemic stroke patients one month after stroke onset. It is not clear, if cognitive impairments after stroke is caused by the mg-deficiency or by the stroke itself. Until now, no studies investigating the relationship between mg-concentration, stroke severity and cognition during treatment course are available. Thus, this study aimed to investigate the relationship between mg-concentration and cognition of stroke patients.

Eligibility

Primary outcome measure(s)

• Serum mg-concentration — day 1
  This study defines a reference value ranging from 1,8 to 2,53 mg/dl.
• Change from Serum mg-concentration from admission at day 28 — day 28
  This study defines a reference value ranging from 1,8 to 2,53 mg/dl.
• Change from Serum mg-concentration from admission at day 72 — day 72
  This study defines a reference value ranging from 1,8 to 2,53 mg/dl.
• Change from Serum mg-concentration from admission at study end — up to 6 month
  This study defines a reference value ranging from 1,8 to 2,53 mg/dl.
• Kölner Neuropsychologische Screening für Schlaganfall-Patienten (KöpSS) — day 3
  The score ranges from 0 to 108 points. If all subtest can be performed, a score \<98 points identify an impaired cognition.
• Change from Kölner Neuropsychologische Screening für Schlaganfall-Patienten (KöpSS) at day 28 — day 28
  The score ranges from 0 to 108 points. If all subtest can be performed, a score \<98 points identify an impaired cognition.
• Change from Kölner Neuropsychologische Screening für Schlaganfall-Patienten (KöpSS) at day 72 — day 72
  The score ranges from 0 to 108 points. If all subtest can be performed, a score \<98 points identify an impaired cognition.
• Change from Kölner Neuropsychologische Screening für Schlaganfall-Patienten (KöpSS) at study end — up to 6 month
  The score ranges from 0 to 108 points. If all subtest can be performed, a score \<98 points identify an impaired cognition.
• National Institutes of Health Stroke Scale — day 1
  0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke; ≥25 points: very severe stroke
• Change from National Institutes of Health Stroke Scale at day 3 — day 3
  0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke; ≥25 points: very severe stroke
• Change from National Institutes of Health Stroke Scale at day 28 — day 28
  0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke; ≥25 points: very severe stroke
• Change from National Institutes of Health Stroke Scale at day 72 — day 72
  0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke; ≥25 points: very severe stroke
• Change from National Institutes of Health Stroke Scale at study end — up to 6 month
  0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke; ≥25 points: very severe stroke
• Lenght of stay — up to 6 month
  Lenght of stay will be assesse at discharge.

Trial sites (1)

More BDH-Klinik Hessisch Oldendorf trials in Germany

Other trials for the same condition